Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial

John C. Wood, Tara Glynos, Alexis Thompson, Patricia Giardina, Paul Harmatz, Barinder P. Kang, Carole Paley, Thomas D. Coates

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

The US04 trial was a multicenter, open-label, single arm trial of deferasirox monotherapy (30-40 mg/kg/day) for 18 months. Cardiac iron response was bimodal with improvements observed in patients with mild to moderate initial somatic iron stores; relationship of cardiac response to labile plasma iron is now presented. Labile plasma iron was measured at baseline, six months, and 12 months. In patients having a favorable cardiac response at 18 months, initial labile plasma iron was elevated in only 31% of patients at baseline and no patient at six or 12 months. Cardiac non-responders had elevated labile plasma iron in 50% of patients at baseline, 50% patients at six months, and 38% of patients at 12 months. Risk of abnormal labile plasma iron and cardiac response increased with initial liver iron concentration. Persistently increased labile plasma iron predicts cardiac nonresponse to deferasirox but labile plasma iron suppression does not guarantee favorable cardiac outcome.

Original languageEnglish (US)
Pages (from-to)1055-1058
Number of pages4
JournalHaematologica
Volume96
Issue number7
DOIs
StatePublished - Jul 2011

Keywords

  • Cardiac T2*
  • Chelation
  • Deferasirox
  • Heart
  • Labile plasma iron
  • MRI
  • Non transferrin bound iron
  • Siderosis
  • Thalassemia

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial'. Together they form a unique fingerprint.

Cite this